soul study semaglutide Oral Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the Randomized Trial ADA 2025: Oral Semaglutide Demonstrates

These GLP-1 agonists reduce weight, improve insulin resistance and seem to be effective at preventing diabetes and lowering the risk of heart disease and stroke. Researchers recently found that the risk of cardiovascular events dropped by around 20% in participants taking semaglutide, the active ingredient in Ozempic and Wegovy

Another difference is that most injectable GLP-1 medications for weight loss are administered once a week

We prioritize a science-backed, empathetic approach to weight loss, ensuring that you feel equipped to handle everything from managing side effects to knowing when its the right time to give back through plasma donation

Private Prescriptions is based on the product's authorised indication and a clinician's assessment of whether treatment is safe and appropriate